Avacta ships SARS-COV-2 Affimer reagents to Cytiva and Adeptrix for diagnostic test development
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, has started shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners. The Group recently reported that it had generated multiple, highly specific Affimer reagents that bind the SARS-COV-2 viral antigen and do not cross-react with SARS, MERS and other closely related […]
